Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation

Mostrar otras versiones (1)

Vaccines against SARS-CoV-2 have been rapidly approved. Although pivotal studies were conducted in healthy volunteers, little information is available on the safety and efficacy of mRNA vaccines in immunocompromised patients, including recipients of allogeneic hematopoietic cell transplantation (all...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Alice, Cicin-Sain, Caroline, Pasin, Chloe, Epp, Selina, Audigé, Annette, Müller, Nicolas J., Nilsson, Jakob, Bankova, Andriyana, Wolfensberger, Nathan, Vilinovszki, Oliver, Nair, Gayathri, Hockl, Philipp, Schanz, Urs, Kouyos, Roger D., Hasse, Barbara, Zinkernagel, Annelies S., Trkola, Alexandra, Manz, Markus G., Abela, Irene A., Müller, Antonia M.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. 2022
Materias:
Full Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802693/
https://www.ncbi.nlm.nih.gov/pubmed/35092892
http://dx.doi.org/10.1016/j.jtct.2022.01.019
Mostrar todas las versiones(2)

Ejemplares similares